Panbela Therapeutics (PBLA) 10-K 25 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 23, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	Panbela Therapeutics, Inc.
Entity Central Index Key	0001029125
Trading Symbol	pbla
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		10,083,872
Entity Public Float			$ 30,195,812
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.001 par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 9,022,000	$ 2,449,000
Prepaid expenses and other current assets	412,000	283,000
Income tax receivable	323,000	361,000
Total current assets	9,757,000	3,093,000
Other noncurrent assets	56,000	51,000
Total assets	9,813,000	3,144,000
Current liabilities:
Accounts payable	554,000	597,000
Accrued expenses	811,000	304,000
Term debt, current portion		116,000
Unsecured promissory note payable		742,000
Total current liabilities	1,365,000	1,759,000
Total liabilities	1,365,000	1,759,000
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2020 and December 31, 2019	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 9,664,427 and 6,631,308 shares issued and outstanding, as of December 31, 2020 and December 31, 2019, respectively	10,000	7,000
Additional paid-in capital	54,848,000	42,331,000
Accumulated deficit	(46,026,000)	(41,258,000)
Accumulated comprehensive (loss) income	(384,000)	305,000
Total stockholders' equity	8,448,000	1,385,000
Total liabilities and stockholders' equity	$ 9,813,000	$ 3,144,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	9,664,427	6,631,308
Common stock, shares outstanding (in shares)	9,664,427	6,631,308

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
General and administrative	$ 3,249	$ 1,973
Research and development	2,505	2,349
Operating loss	(5,754)	(4,322)
Other income (expense):
Interest expense	(17)	(2,194)
Gain on debt forgiveness	103
Other income (expense)	605	(99)
Total other income (expense)	691	(2,293)
Loss before income tax benefit	(5,063)	(6,615)
Income tax benefit	295	415
Net loss	(4,768)	(6,200)
Foreign currency translation adjustment	(689)	22
Comprehensive loss	$ (5,457)	$ (6,178)
Basic and diluted net loss per share (in dollars per share)	$ (0.62)	$ (1.09)
Weighted average shares outstanding - basic and diluted (in shares)	7,732,882	5,700,314

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]	Underwritten Public Offering [Member]Common Stock [Member]	Underwritten Public Offering [Member]Additional Paid-in Capital [Member]	Underwritten Public Offering [Member]Retained Earnings [Member]	Underwritten Public Offering [Member]AOCI Attributable to Parent [Member]	Underwritten Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2018											5,077,000
Balances at Dec. 31, 2018											$ 5	$ 35,038	$ (35,058)	$ 283	$ 268
Beneficial conversion feature on convertible notes payable												353			353
Warrants issued												419			419
Common stock converted into convertible notes payable (in shares)											(7,000)
Common stock converted into convertible notes payable												(25)			(25)
Conversion of convertible notes payable and accrued interest into common stock (in shares)											652,000
Conversion of convertible notes payable and accrued interest into common stock											$ 1	2,280			2,281
Sale of common stock and warrants (in shares)					909,209						909,000
Sale of common stock and warrants											$ 1	3,159			3,160
Warrants issued in exchange for modification of term debt												14			14
Stock-based compensation												1,093			1,093
Net loss													(6,200)		(6,200)
Foreign currency translation adjustment														22	22
Balances (in shares) at Dec. 31, 2019											6,631,000
Balances at Dec. 31, 2019											$ 7	42,331	(41,258)	305	1,385
Warrants issued												228			228
Common stock converted into convertible notes payable
Sale of common stock and warrants (in shares)	437,000					2,545,000
Sale of common stock and warrants		$ 1,746			$ 1,746	$ 3	$ 9,218			$ 9,221
Stock-based compensation												1,205			1,205
Net loss													(4,768)		(4,768)
Foreign currency translation adjustment														(689)	(689)
Exercise of warrants for cash (in shares)											43,000
Exercise of warrants for cash												120			120
Exercise of warrants, cashless (in shares)											8,000
Exercise of warrants, cashless
Balances (in shares) at Dec. 31, 2020											9,664,000
Balances at Dec. 31, 2020											$ 10	$ 54,848	$ (46,026)	$ (384)	$ 8,448

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (4,768)	$ (6,200)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,205	1,093
Amortization of debt discount		2,066
Amortization of debt issuance costs		12
Forgiveness of Paycheck Protection Program loan	(103)
Non-cash interest expense		102
Changes in operating assets and liabilities:
Income tax receivable	(2)	(31)
Prepaid expenses and other current assets	67	(174)
Accounts payable	(747)	301
Accrued liabilities	494	92
Net cash used in operating activities	(3,854)	(2,739)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants net of offering costs of $2 and $16, respectively	1,746	3,160
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $1,165	9,335
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7		810
Proceeds from exercise of warrants	120
Proceeds from Paycheck Protection Program loan	103
Repayments of demand note	(743)	(25)
Repayments of term debt	(117)	(161)
Net cash provided by financing activities	10,444	3,784
Effect of exchange rate changes on cash	(17)	(1)
Net change in cash	6,573	1,044
Cash at beginning of period	2,449	1,405
Cash at end of period	9,022	2,449
Supplemental disclosure of cash flow information:
Cash paid during period for interest	8	14
Supplemental disclosure of non-cash transactions:
Warrants issued for future services	228
Warrants issued to underwriter	353
Amortization of warrants as offering costs	114
Beneficial conversion feature on convertible notes		353
Warrants issued with convertible notes		419
Common stock converted into convertible notes payable		(25)
Warrants issued in exchange for modificaton of term debt		14
Conversion of convertible notes payable and accrued interest into common stock		2,281
Issuance of unsecured promissory note in exchange of vendor accounts payable		$ 742

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Proceeds from the sale of convertible promissory notes, offering costs		$ 7
Private Placement [Member]
Proceeds from issuance of common stock and warrants, issuance costs	$ 2	$ 16
Underwritten Public Offering [Member]
Proceeds from issuance of common stock and warrants, issuance costs	$ 1,165

Note 1 - Business

Note 1 - Business	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Panbela Therapeutics, Inc., formally known as Sun BioPharma, Inc., and its wholly owned subsidiary Panbela Therapeutics Pty Ltd, formally known as Sun BioPharma Australia Pty Ltd, (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP- 101, September 21, 2011. May 24, 2013

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $46.0 2011. December 31, 2020 $4.8 $3.9 101. December 31, 2020, $9.0 $8.4 $8.4 The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not 101, In March 2020, 19” 19, 2020 two not 19 19 19 April 2020, six not May 2020, fourth 2020. no no

Note 3 - Liquidity and Manageme

Note 3 - Liquidity and Management Plans	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	3. Liquidity and Management Plans We will need to seek additional sources of funds to support our current business plans. We may no not If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that may 101 third 101 On September 1, 2020, 2,545,454 $9.3 June 30, 2020, $1.7 first 2022. In closings occurring in the August October 2019 909,209 $3.2 Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our SBP- 101 101 not not no

Note 4 - Summary of Significant

Note 4 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	4. Summary of Significant Accounting Policies Basis of presentation We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31. Principles of consolidation The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Panbela Therapeutics, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may December 31, 2020, $8.7 not Beneficial conversion feature For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (“BCF”) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt. Research and development costs Research and development costs include expenses incurred in the conduct of our Phase 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not The fair value of restricted stock units is calculated as the fair value of the underlying common stock as of the date of grant. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not December 31, 2020 2019. Foreign currency translation The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2020 2019, Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following outstanding potential common shares were not not December 31, 2020 2019 Employee and non-employee stock options 2,137,499 1,744,811 Restricted stock units 11,500 - Common stock issuable under common stock purchase warrants 6,556,468 3,422,099 8,705,467 5,166,910 Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, no December 15, 2020.

Note 5 - Accrued Expenses

Note 5 - Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accrued Liabilities [Text Block]	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2020 2019 Clinical trial and related expenses $ 186 $ 147 Incentive compensation 497 - Professional services 98 125 Other 30 32 Total accrued liabilities $ 811 $ 304

Note 6 - Indebtedness

Note 6 - Indebtedness	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Indebtedness 2018 In December 2018 January 2019, “2018 $2.2 2018 June 30, 2019 10.0% 2018 1 June 30, 2019 2 $6.0 $3.50 2018 two $3.50 2018 1,243,498 December January $4.50 5 $2.5 2018 $0.9 2018 June 30, 2019, $2.2 $105,000 $3.50 651,758 Term debt The unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. was paid in full on December 31, 2020. 2019 PPP loan On May 1, 2020, $103,000 March 27, 2020. 100% may December 30, 2020 2020 Other indebtedness On October 6, 2020, $742,000 not

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies License agreement On December 22, 2011, first December 12, 2016 ( October 3, 2019 ( 2.5% 5% 1 ten first 2 The amended license agreement remains subject to customary and usual termination provisions. The Company must also pay an annual license maintenance fee of $10,000.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Stockholders Equity Public offering of common stock and warrants On September 1, 2020, 2,545,454 five $4.54. $10.5 $81,000 $9.3 1. August 28, 2020. 3, Underwriter warrant to purchase common stock On September 1, 2020, five 127,273 $4.537. $353,000, Exercise of Warrants to purchase common stock During the quarter ended December 31, 2020, 15,000 $4.54 1. On September 1, 2020, 35,665 $1.875 27,500 $52,000 15,000 8,165 Private placements of common stock and warrants On closings occurring in May June 2020, 437,000 $1.7 $50,000 five $6.00. 3, Warrants to purchase common stock issued for future services On February 21, 2020, five 75,000 $6.49 $228,000 one $114,000, September 1, 2020 2019 On closings occurring in 2019, 909,209 $3.2 $240,000 five $4.00 3, Shares reserved Shares of common stock reserved for future issuance were as follows as of December 31, 2020: Stock options outstanding 2,137,499 Restricted stock units outstanding 11,500 Shares available for grant under equity incentive plan 883,001 Common shares issuable under outstanding common stock purchase warrants 6,556,468 9,588,468

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9. Stock-Based Compensation 2016 The. 2016 April 9, 2020 ( “2016 2016 2016 not 2016 ten 2016 2,800,000 December 31, 2020, 1,905,499 11,500 2016 883,001 2011 Prior to approval of the 2016 2011 “2011 2016 2011 2011 2011 ten zero two December 31, 2020, 232,000 2011 We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest. A summary of option activity is as follows: Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2019 1,032,211 $ 8.90 $ 169,495 Granted 733,400 3.42 Exercised - - Cancelled - - Forfeitures (20,800 ) 15.10 Balance at December 31, 2019 1,744,811 $ 6.53 $ 1,047,197 Granted 425,648 7.48 Exercised - - Cancelled (32,360 ) 2.42 Forfeitures (600 ) 15.10 Balance at December 31, 2020 2,137,499 $ 6.77 $ 388,461 A summary of the status of our unvested shares during the two December 31, 2020 Shares Under Option Weighted Average Grant Date Fair Value Unvested at January 1, 2019 42,500 $ 4.83 Granted 733,400 2.09 Vested (378,025 ) 2.41 Forfeitures - - Unvested at December 31, 2019 397,875 $ 2.03 Granted 425,648 5.39 Vested (322,437 ) 3.14 Forfeitures - - Unvested at December 31, 2020 501,086 $ 4.17 Information about stock options outstanding, vested and expected to vest as of December 31, 2020, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 22,000 1.92 $ 1.018 22,000 1.92 $2.275 - $2.50 22,000 3.20 $ 2.439 22,000 3.20 $2.95 - $3.70 762,100 7.37 $ 3.038 600,650 7.09 $4.50 - $8.10 751,900 7.68 $ 6.241 571,300 7.15 $9.99 - $10.10 266,048 8.93 $ 9.994 107,012 8.03 $15.10 313,451 5.41 $ 15.100 313,451 5.41 Totals 2,137,499 7.29 $ 6.773 1,636,413 6.73 As of December 31, 2020, not $2.1 1.8 The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2020 2019: 2020 2019 Common stock fair value $4.82 - $9.99 $2.95 - $5.00 Risk-free interest rate 0.29% - 0.39% 1.55% - 2.25% Expected dividend yield 0 0 Expected Option life (in years) 5.00 - 5.75 5.00 - 5.50 Expected stock price volatility 90% 72% Nonemployee stock-based compensation We account for stock options granted to nonemployees in accordance with Accounting Standards Update (“ASU”) 2019 07, 718 $261,000 $288,000 2020 2019, Restricted stock units The number and weighted average grant date fair value of restricted non vested common stock for the most recent completed fiscal year is as follows: Number of Restricted Shares Weighted Average Grant Date Fair Value Restricted nonvested at January 1, 2020 - $ - Granted in 2020 11,500 3.45 Vested in 2020 - - Restricted nonvested at December 31, 2020 11,500 $ 3.45 As of December 31, 2020, not $33,000, 0.4 Stock compensation expense includes expense related to restricted stock units of approximately $7,000 2020.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes We have incurred net operating losses since inception. We have not On December 31, 2020 2019, $323,000 $361,000, Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards. The significant components of our deferred tax assets and liabilities are as follows (in thousands): December 31, Deferred tax assets (liabilities) 2020 2019 Net operating loss carryforwards $ 7,660 $ 6,307 Research credit carryforwards 235 235 Stock-based compensation 1,498 1,230 Other 70 72 Deferred tax assets 9,463 7,844 Valuation allowance (9,463 ) (7,844 ) Net deferred tax asset $ - $ - Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry-forward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently not A reconciliation of the statutory tax rates and the effective tax rates is as follows: Year Ended December 31, 2020 2019 Statutory rate 21.0 % 21.0 % Permanent differences 1.7 (5.9 ) Valuation allowance (26.5 ) (32.4 ) Foreign research incentives 5.4 5.7 Deferred true-up - 16.3 Other 3.8 1.0 Effective rate 5.4 % 5.7 % Net operating losses and tax credit carryforwards as of December 31, 2020, (In Thousands) Amount Expiration Years Net operating losses--federal 12,958 Expires beginning 2031 2018 to 2020 net operating loss -- federal 6,148 Never expires Tax credits--federal 235 Beginning 2041 Utilization of the net operating loss carryforwards and credits may not 382 The Company is subject to taxation in the United States and Australia. Tax returns for the year ended December 31, 2016 December 31, 2015

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Events Cash Exercise of Outstanding Warrants Between February 5 March 23, 2021, 223,938 $4.54 $1.0 Cashless Exercise of Outstanding Warrants Between February 2 March 23, 2021, 531,140 188,607

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31.
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Panbela Therapeutics, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may December 31, 2020, $8.7 not
Beneficial Conversion Feature, Policy [Policy Text Block]	Beneficial conversion feature For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (“BCF”) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our Phase 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not The fair value of restricted stock units is calculated as the fair value of the underlying common stock as of the date of grant.
Income Tax, Policy [Policy Text Block]	Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not December 31, 2020 2019.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2020 2019,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following outstanding potential common shares were not not December 31, 2020 2019 Employee and non-employee stock options 2,137,499 1,744,811 Restricted stock units 11,500 - Common stock issuable under common stock purchase warrants 6,556,468 3,422,099 8,705,467 5,166,910
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, no December 15, 2020.

Note 4 - Summary of Significa_2

Note 4 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2020 2019 Employee and non-employee stock options 2,137,499 1,744,811 Restricted stock units 11,500 - Common stock issuable under common stock purchase warrants 6,556,468 3,422,099 8,705,467 5,166,910

Note 5 - Accrued Expenses (Tabl

Note 5 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2020 2019 Clinical trial and related expenses $ 186 $ 147 Incentive compensation 497 - Professional services 98 125 Other 30 32 Total accrued liabilities $ 811 $ 304

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	Stock options outstanding 2,137,499 Restricted stock units outstanding 11,500 Shares available for grant under equity incentive plan 883,001 Common shares issuable under outstanding common stock purchase warrants 6,556,468 9,588,468

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2019 1,032,211 $ 8.90 $ 169,495 Granted 733,400 3.42 Exercised - - Cancelled - - Forfeitures (20,800 ) 15.10 Balance at December 31, 2019 1,744,811 $ 6.53 $ 1,047,197 Granted 425,648 7.48 Exercised - - Cancelled (32,360 ) 2.42 Forfeitures (600 ) 15.10 Balance at December 31, 2020 2,137,499 $ 6.77 $ 388,461
Schedule of Nonvested Share Activity [Table Text Block]	Shares Under Option Weighted Average Grant Date Fair Value Unvested at January 1, 2019 42,500 $ 4.83 Granted 733,400 2.09 Vested (378,025 ) 2.41 Forfeitures - - Unvested at December 31, 2019 397,875 $ 2.03 Granted 425,648 5.39 Vested (322,437 ) 3.14 Forfeitures - - Unvested at December 31, 2020 501,086 $ 4.17
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 22,000 1.92 $ 1.018 22,000 1.92 $2.275 - $2.50 22,000 3.20 $ 2.439 22,000 3.20 $2.95 - $3.70 762,100 7.37 $ 3.038 600,650 7.09 $4.50 - $8.10 751,900 7.68 $ 6.241 571,300 7.15 $9.99 - $10.10 266,048 8.93 $ 9.994 107,012 8.03 $15.10 313,451 5.41 $ 15.100 313,451 5.41 Totals 2,137,499 7.29 $ 6.773 1,636,413 6.73
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Common stock fair value $4.82 - $9.99 $2.95 - $5.00 Risk-free interest rate 0.29% - 0.39% 1.55% - 2.25% Expected dividend yield 0 0 Expected Option life (in years) 5.00 - 5.75 5.00 - 5.50 Expected stock price volatility 90% 72%
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Restricted Shares Weighted Average Grant Date Fair Value Restricted nonvested at January 1, 2020 - $ - Granted in 2020 11,500 3.45 Vested in 2020 - - Restricted nonvested at December 31, 2020 11,500 $ 3.45

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, Deferred tax assets (liabilities) 2020 2019 Net operating loss carryforwards $ 7,660 $ 6,307 Research credit carryforwards 235 235 Stock-based compensation 1,498 1,230 Other 70 72 Deferred tax assets 9,463 7,844 Valuation allowance (9,463 ) (7,844 ) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2020 2019 Statutory rate 21.0 % 21.0 % Permanent differences 1.7 (5.9 ) Valuation allowance (26.5 ) (32.4 ) Foreign research incentives 5.4 5.7 Deferred true-up - 16.3 Other 3.8 1.0 Effective rate 5.4 % 5.7 %
Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block]	(In Thousands) Amount Expiration Years Net operating losses--federal 12,958 Expires beginning 2031 2018 to 2020 net operating loss -- federal 6,148 Never expires Tax credits--federal 235 Beginning 2041

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance	$ (46,026)	$ (41,258)
Net Income (Loss) Attributable to Parent, Total	(4,768)	(6,200)
Net Cash Provided by (Used in) Operating Activities, Total	(3,854)	(2,739)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	9,022	2,449
Working Capital	8,400
Stockholders' Equity Attributable to Parent, Ending Balance	$ 8,448	$ 1,385	$ 268

Note 3 - Liquidity and Manage_2

Note 3 - Liquidity and Management Plans (Details Textual) - USD ($)	Sep. 01, 2020	Jun. 30, 2020	Jun. 30, 2020	Oct. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Issuance of Common Stock, Net					$ 9,335,000
Proceeds from Issuance of Private Placement					$ 1,746,000	$ 3,160,000
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,545,454
Proceeds from Issuance of Common Stock, Net	$ 9,300,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		437,000		909,209		909,209
Proceeds from Issuance of Private Placement		$ 1,700,000	$ 1,700,000	$ 3,200,000		$ 3,200,000

Note 4 - Summary of Significa_3

Note 4 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	Dec. 31, 2020USD ($)
Cash, Uninsured Amount	$ 8.7

Note 4 - Summary of Significa_4

Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities (in shares)	8,705,467	5,166,910
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	2,137,499	1,744,811
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	11,500
Warrant [Member]
Anti-dilutive securities (in shares)	6,556,468	3,422,099

Note 5 - Accrued Expenses - Acc

Note 5 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Clinical trial and related expenses	$ 186	$ 147
Incentive compensation	497
Professional services	98	125
Other	30	32
Accrued liabilities	$ 811	$ 304

Note 6 - Indebtedness (Details

Note 6 - Indebtedness (Details Textual) - USD ($)	Oct. 06, 2020	May 01, 2020	Jun. 30, 2019	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Convertible Debt						$ 810,000
Intrinsic Value of Convertible Debt with Conversion Feature						$ 353,000
Proceeds from Paycheck Protection Program Under CARES Act		$ 103,000
Conversion from Debt to Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 3.50
Debt Conversion, Original Debt, Amount			$ 2,200,000
Debt Conversion, Accrued Interest, Amount			$ 105,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			651,758
Warrants In Connection with 2018 Convertible Notes Payable [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,243,498
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 4.50
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants Upon Issuance, Fair Value				$ 2,500,000
The 2018 Notes [Member]
Proceeds from Convertible Debt				2,200,000
Convertible Debt, Mandatory Conversion Threshold, Gross Proceeds from Sale of Equity Securities				6,000,000
Class of Warrant or Right, Principal Amount of Every Amount Of Notes Purchased				3.50
Intrinsic Value of Convertible Debt with Conversion Feature				$ 900,000
The 2018 Notes [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage				10.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)				$ 3.50
Unsecured Promissory Note [Member]
Repayments of Unsecured Debt	$ 742,000

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual) - Licensing Agreement with University of Florida Research Foundation [Member]	Dec. 22, 2011USD ($)
Royalty Term (Year)	10 years
Annual License Maintenance Fee	$ 10,000
Minimum [Member]
Royalty Fee Percentage of Net Sales	2.50%
Maximum [Member]
Royalty Fee Percentage of Net Sales	5.00%

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	Sep. 01, 2020	Jun. 30, 2020	Dec. 31, 2020	Jun. 30, 2020	Oct. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Feb. 21, 2020
Proceeds from Issuance of Common Stock, Net						$ 9,335,000
Stock Issued During Period, Shares, Warrants Exercised (in shares)			15,000
Stock Issued During Period, Value, Exercise of Warrants for Cash						120,000
Proceeds from Issuance of Private Placement						$ 1,746,000	3,160,000
Directors and Officers [Member]
Proceeds from Issuance of Private Placement							$ 240,000
Underwritten Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.537
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	127,273
Warrants and Rights Outstanding	$ 353,000
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 1.875		$ 4.54
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	15,000
Warrants in Connection with the Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)		5 years		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6		$ 6
Warrants Issued for Future Services [Member]
Warrants and Rights Outstanding, Term (Year)								5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 6.49
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								75,000
Warrants and Rights Outstanding								$ 228,000
Warrants in Connection with Securities Purchase Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 4
Class of Warrant or Right, Expiration Term (Year)							5 years
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,545,454
Proceeds from Issuance or Sale of Equity, Total	$ 10,500,000
Proceeds from Issuance of Common Stock, Net	$ 9,300,000
Stock Issued During Period, Shares, Warrants Exercised (in shares)	35,665
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)	27,500
Stock Issued During Period, Value, Exercise of Warrants for Cash	$ 52,000
Stock Issued During Period, Shares, Exercise of Warrants on Cashless Basis (in shares)	8,165
Warrants Issued, Cost Capitalized, Against Proceeds Received in Offering	$ 114,000
Underwritten Public Offering [Member] | Directors and Officers [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 81,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		437,000			909,209		909,209
Proceeds from Issuance of Private Placement		$ 1,700,000		$ 1,700,000	$ 3,200,000		$ 3,200,000
Private Placement [Member] | Directors and Officers [Member]
Proceeds from Issuance of Private Placement		$ 50,000

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Dec. 31, 2020shares
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	9,588,468
Warrant [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	6,556,468
Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,137,499
Restricted Stock Units (RSUs) [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	11,500
Shares Available for Grant Under Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	883,001

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	9,588,468
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	2,137,499	1,744,811	1,032,211
Restricted Stock Units (RSUs) [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	11,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	11,500
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 33,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	146 days
Share-based Payment Arrangement, Expense	$ 7,000
Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,137,499
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 2,100,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 292 days
Non-Employee Stock Option [Member]
Share-based Payment Arrangement, Expense	$ 261,000	$ 288,000
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	1,905,499
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	883,001
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	11,500
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	232,000
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	0 years
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Balance, shares available for grant (in shares)	1,744,811	1,032,211
Balance, weighted average exercise price per share (in dollars per share)	$ 6.53	$ 8.90
Aggregate intrinsic value	$ 388,461	$ 1,047,197	$ 169,495
Granted, shares available for grant (in shares)	425,648	733,400
Granted, weighted average exercise price per share (in dollars per share)	$ 7.48	$ 3.42
Cancelled, shares available for grant (in shares)	(32,360)
Forfeitures , shares available for grant (in shares)	(600)	(20,800)
Forfeitures, weighted average exercise price per share (in dollars per share)	$ 15.10	$ 15.10
Cancelled, weighted average exercise price per share (in dollars per share)	$ 2.42
Balance, shares available for grant (in shares)	2,137,499	1,744,811
Balance, weighted average exercise price per share (in dollars per share)	$ 6.77	$ 6.53

Note 9 - Stock-based Compensa_5

Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Unvested, shares under option (in shares)	397,875	42,500
Unvested, weighted average grant-date fair value (in dollars per share)	$ 2.03	$ 4.83
Granted, shares under option (in shares)	425,648	733,400
Granted, weighted average grant-date fair value (in dollars per share)	$ 5.39	$ 2.09
Vested, shares under option (in shares)	(322,437)	(378,025)
Vested, weighted average grant-date fair value (in dollars per share)	$ 3.14	$ 2.41
Forfeitures (in shares)
Forfeitures (in dollars per share)
Unvested, shares under option (in shares)	501,086	397,875
Unvested, weighted average grant-date fair value (in dollars per share)	$ 4.17	$ 2.03

Note 9 - Stock-based Compensa_6

Note 9 - Stock-based Compensation - Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Options outstanding (in shares) | shares	2,137,499
Options outstanding, weighted average remaining contractual life (Year)	7 years 105 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.773
Options excercisable (in shares) | shares	1,636,413
Options excercisable, weighted average remaining contractual life (Year)	6 years 266 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 0.875
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	22,000
Options outstanding, weighted average remaining contractual life (Year)	1 year 335 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.018
Options excercisable (in shares) | shares	22,000
Options excercisable, weighted average remaining contractual life (Year)	1 year 335 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.275
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) | shares	22,000
Options outstanding, weighted average remaining contractual life (Year)	3 years 73 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.439
Options excercisable (in shares) | shares	22,000
Options excercisable, weighted average remaining contractual life (Year)	3 years 73 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 3.70
Options outstanding (in shares) | shares	762,100
Options outstanding, weighted average remaining contractual life (Year)	7 years 135 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.038
Options excercisable (in shares) | shares	600,650
Options excercisable, weighted average remaining contractual life (Year)	7 years 32 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) | shares	751,900
Options outstanding, weighted average remaining contractual life (Year)	7 years 248 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.241
Options excercisable (in shares) | shares	571,300
Options excercisable, weighted average remaining contractual life (Year)	7 years 54 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9.99
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) | shares	266,048
Options outstanding, weighted average remaining contractual life (Year)	8 years 339 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.994
Options excercisable (in shares) | shares	107,012
Options excercisable, weighted average remaining contractual life (Year)	8 years 10 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Options outstanding (in shares) | shares	313,451
Options outstanding, weighted average remaining contractual life (Year)	5 years 149 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.10
Options excercisable (in shares) | shares	313,451
Options excercisable, weighted average remaining contractual life (Year)	5 years 149 days

Note 9 - Stock-based Compensa_7

Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	90.00%	72.00%
Minimum [Member]
Common stock fair value (in dollars per share)	$ 4.82	$ 2.95
Risk-free interest rate	0.29%	1.55%
Expected option life (Year)	5 years	5 years
Expected stock price volatility
Maximum [Member]
Common stock fair value (in dollars per share)	$ 9.99	$ 5
Risk-free interest rate	0.39%	2.25%
Expected option life (Year)	5 years 273 days	5 years 182 days
Expected stock price volatility

Note 9 - Stock-based Compensa_8

Note 9 - Stock-based Compensation - Nonvested Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Restricted nonvested (in shares) | shares
Restricted nonvested, weighted average grant date fair value (in dollars per share) | $ / shares
Granted, restricted shares (in shares) | shares	11,500
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 3.45
Vested, restricted shares (in shares) | shares
Vested, weighted average grant date fair value (in dollars per share) | $ / shares
Restricted nonvested (in shares) | shares	11,500
Restricted nonvested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 3.45

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes Receivable, Current	$ 323,000	$ 361,000
Domestic Tax Authority [Member]
Open Tax Year	2015 2016 2017 2018 2019

Note 10 - Income Taxes - Deferr

Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards	$ 7,660	$ 6,307
Research credit carryforwards	235	235
Stock-based compensation	1,498	1,230
Other	70	72
Deferred tax assets	9,463	7,844
Valuation allowance	(9,463)	(7,844)
Net deferred tax asset

Note 10 - Income Taxes - Income

Note 10 - Income Taxes - Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statutory rate	21.00%	21.00%
Permanent differences	1.70%	(5.90%)
Valuation allowance	(26.50%)	(32.40%)
Foreign research incentives	5.40%	5.70%
Deferred true-up		16.30%
Other	3.80%	1.00%
Effective rate	5.40%	5.70%

Note 10 - Income Taxes - Net Op

Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) - Domestic Tax Authority [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Net operating losses--federal	$ 12,958
Tax credits--federal	$ 235
Earliest Tax Year [Member]
Net operating losses--federal	2031
Tax credits--federal	2041
Tax Year 2018 [Member]
Net operating losses--federal	$ 6,148

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	2 Months Ended		3 Months Ended	12 Months Ended
	Mar. 23, 2021	Mar. 23, 2021	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Stock Issued During Period, Shares, Warrants Exercised (in shares)			15,000
Proceeds from Warrant Exercises				$ 120
Subsequent Event [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)		223,938
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.54	$ 4.54
Proceeds from Warrant Exercises		$ 1,000
Subsequent Event [Member] | Warrants Exercised on Net, Cashless Basis [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	531,140	531,140
Stock Issued During Period, Shares, Exercise of Warrants on Cashless Basis (in shares)	188,607